Surf Therapeutics, a clinical-stage company developing non-invasive ultrasound neuromodulation therapies to treat immune-mediated diseases, today reported positive first-in-human study results and announced the close of an extension seed financing round, bringing the company's total funding to approximately $6 million.

This financing builds on their previous seed round including participation from SOSV, VVP Ignite, TMC Venture Fund, General Inception, Elderberry Ventures, Evoce Capital and others, along with other angel investors like Mir Imran (Rani Therapeutics).

Surf Therapeutics is a clinical-stage company pioneering the development of non-invasive ultrasound neuromodulation technologies to modulate immune-related pathways. Its SUSTAIN™ platform is designed to engage the body's natural anti-inflammatory pathway without surgery or implanted hardware, enabling safe, at-home use and scalable access to therapy.